Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly ...

But Hims & Hers shares are unlikely to sustain these gains over time. The stock is still down some 38% versus its ...

Shares of Hims & Hers Health (NYSE: HIMS) skyrocketed after the telemedicine platform came to an agreement with Novo Nordisk (NYSE: NVO) to sell the drugmaker's popular GLP-1 weight loss drugs. The ...

Shares of telehealth company Hims & Hers skyrocketed Monday after the company struck a deal with Danish drugmaker Novo Nordisk to sell its GLP-1 weight-loss medications, ending the feud between the ...

Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and Wegovy copycat drugs.

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after ...

Hims stock surged more than 40% Monday morning on news that Novo Nordisk will distribute its weight loss drugs through the Hims platform.

Hims & Hers Health Inc was upgraded to “Neutral” from “Underperform” by Bank of America, which said a new agreement with Novo Nordisk removes a key legal risk that had weighed on the telehealth ...